- Home
- Publications
- Publication Search
- Publication Details
Title
The Key Role of NAD+ in Anti-Tumor Immune Response: An Update
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-16
DOI
10.3389/fimmu.2021.658263
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular dynamics of targeting CD38 in multiple myeloma
- (2021) Fabio Malavasi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity
- (2020) Romana R. Gerner et al. LEUKEMIA
- The Role of Nicotinamide in Cancer Chemoprevention and Therapy
- (2020) Ilias P. Nikas et al. Biomolecules
- Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses
- (2020) Alak Manna et al. Blood Advances
- Nicotinamide inhibits melanoma in vitro and in vivo
- (2020) Francesca Scatozza et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- STING cyclic dinucleotide sensing originated in bacteria
- (2020) Benjamin R. Morehouse et al. NATURE
- Molecular and spatial mechanisms governing STING signalling
- (2020) Katherine R. Balka et al. FEBS Journal
- Targeting CD38-dependent NAD+ metabolism to mitigate multiple organ fibrosis
- (2020) Bo Shi et al. iScience
- The NADase CD38 is induced by factors secreted from senescent cells providing a potential link between senescence and age-related cellular NAD+ decline
- (2019) Claudia Chini et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia
- (2019) Alak Manna et al. CLINICAL CANCER RESEARCH
- CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy
- (2019) Alberto L. Horenstein et al. Frontiers in Immunology
- ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors—A STING in the Tale of ENPP1
- (2019) Kenneth I. Onyedibe et al. MOLECULES
- Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
- (2019) Thomas G. Martin et al. Cells
- The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors
- (2019) Jessica M. Konen et al. Cells
- CD38-NAD + Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
- (2018) Shilpak Chatterjee et al. Cell Metabolism
- Immunomodulatory effects of CD38-targeting antibodies
- (2018) Niels W.C.J. van de Donk IMMUNOLOGY LETTERS
- Canonical and non-canonical adenosinergic pathways
- (2018) E. Ferretti et al. IMMUNOLOGY LETTERS
- Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1
- (2018) Kazuki Kato et al. Nature Communications
- Role of CD38 Expression in Diagnosis and Pathogenesis of Chronic Lymphocytic Leukemia and Its Potential as Therapeutic Target
- (2015) Simone Burgler CRITICAL REVIEWS IN IMMUNOLOGY
- A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation
- (2015) Fabio Morandi et al. Oncotarget
- NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
- (2015) Alberto Horenstein et al. Cells
- A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
- (2013) Alberto L Horenstein et al. OncoImmunology
- CD38 and chronic lymphocytic leukemia: a decade later
- (2011) F. Malavasi et al. BLOOD
- NAD+ -metabolizing ecto-enzymes shape tumor-host interactions: The chronic lymphocytic leukemia model
- (2011) Tiziana Vaisitti et al. FEBS LETTERS
- Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
- (2008) Alan G. Ramsay et al. JOURNAL OF CLINICAL INVESTIGATION
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
- (2008) Fabio Malavasi et al. PHYSIOLOGICAL REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started